Oncolytics Biotech Inc. filed a Form 8-K on October 27, 2026, announcing updated data from Cohort 4 of the GOBLET study evaluating pelareorep and atezolizumab in second-line and later squamous cell anal cancer.

Key Highlights

  • Study update: Updated data from Cohort 4 of the GOBLET study was announced on October 27, 2026.
  • Treatment combination: Cohort 4 evaluates pelareorep and atezolizumab together.
  • Target indication: The cohort focuses on second-line and later squamous cell anal cancer patients.
  • Disclosure method: The announcement was made via a press release, furnished as Exhibit 99.1.
  • Furnished, not filed: The filing states the disclosure "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

GOBLET Study Cohort 4: Pelareorep and Atezolizumab in Squamous Cell Anal Cancer

According to the filing, Oncolytics Biotech Inc. (NASDAQ:ONCY) issued a press release on October 27, 2026, disclosing updated data from Cohort 4 of the GOBLET study. The study is evaluating the combination of pelareorep and atezolizumab specifically in patients with second-line and later squamous cell anal cancer, as described under Item 8.01 of the 8-K.

The company disclosed the announcement through a current report filed under Item 8.01 ("Other Events"), with the full press release attached as Exhibit 99.1. The filing explicitly states that the information furnished under Item 8.01 and in Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." The specific data results from Cohort 4 are contained in the press release exhibit and are not reproduced within the body of the 8-K itself.

The report was signed by Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc., on October 27, 2026. The company is incorporated in Nevada and lists its principal offices at 4350 Executive Drive, Suite 325, San Diego, CA 92121.

What Was Disclosed

Oncolytics Biotech filed an 8-K on October 27, 2026, furnishing updated clinical data from Cohort 4 of the GOBLET study, which is evaluating pelareorep combined with atezolizumab in second-line and later squamous cell anal cancer, via an attached press release.